SENSITIVE QUANTITATIVE DETECTION OF SARS-CoV-2 USING DIGITAL WARM-START CRISPR ASSAY
OwnerXiong Ding, Changchun Liuinventors
Life of this patent
Estimating the term…
Abstract
The disclosure provides materials and methods for detection of pathogens. In particular, the disclosure provides primers and compositions for detection of viral pathogens, such as SARS-CoV-2. In addition, the disclosure provides a warm-start digital CRISPR assay for detection of viral pathogens, including SARS-CoV-2.
Claims34
A digital warm-start assay for detecting a target in a sample, assay comprising:
- a. contacting a sample with a warm-start CRISPR reaction mixture, the warm-start CRISPR reaction mixture comprising a Cas endonuclease, a target-specific crRNA, outer primers for amplification of the target, phosphorothioated inner primers for amplification of the target, and pyrophosphatase;
- b. partitioning the warm-start CRISPR reaction mixture into a plurality of microwells;
- c. amplifying the target, if present in the sample, by isothermal amplification;
- and
- d. detecting a signal in each of the plurality of microwells, wherein detection of the signal in a given microwell indicates the presence of the target in the microwell.
A digital warm-start assay for detecting a target in a sample, assay comprising:
- a. providing a warm-start CRISPR reaction mixture, the warm-start CRISPR reaction mixture comprising a Cas endonuclease, a target-specific crRNA, outer primers for isothermal amplification of the target, phosphorothioated inner primers for isothermal amplification of the target, and pyrophosphatase;
- b. partitioning the warm-start CRISPR reaction mixture into a plurality of microwells, wherein each of the plurality of microwells comprises a sample;
- c. amplifying the target, if present in the sample, by isothermal amplification;
- and
- d. detecting a signal in each of the plurality of microwells, wherein a detectable signal in a given microwell indicates the presence of the target in the microwell.
The method of any one of the preceding claims, wherein the warm-start CRISPR reaction mixture further comprises a forward competition primer and a reverse competition primer.
The method of any one of the preceding claims, wherein the warm-start CRISPR reaction mixture further comprises a DNA polymerase.
The method of any one of the preceding claims, wherein the warm-start CRISPR reaction mixture further comprises a reverse transcriptase.
The method any one of the preceding claims, wherein isothermal amplification comprises incubating the warm-start CRISPR reaction mixture at a temperature of about 50° C.-60° C. for at least about 10 minutes.
The method of any one of the preceding claims, wherein the target is viral nucleic acid.
The method of any one of the preceding claims, wherein the outer primers comprise a forward outer primer and a reverse outer primer, wherein the forward outer primer comprises a nucleotide sequence having at least 90% sequence identity to SEQ ID NO:
- 1 and wherein the reverse outer primer comprises a nucleotide sequence having at least 90% sequence identity to SEQ ID NO:
- 2.
The method of any one of the preceding claims, wherein the phosphorothioated inner primers comprise a forward inner primer and a reverse inner primer, wherein the forward inner primer comprises a nucleotide sequence having at least 90% sequence identity to SEQ ID NO:
- 4, and wherein the reverse inner primer comprises a nucleotide sequence having at least 90% sequence identity to SEQ ID NO:
- 6.
The method of any one of the preceding claims, wherein the warm-start CRISPR reaction mixture comprises less than 0.4 U/μl pyrophosphatase.
The method of any one of the preceding claims, wherein the sample comprises a nasal sample, a nasopharyngeal sample, an oropharyngeal sample, a mid-turbinate sample, or a saliva sample.
The method of any one of the preceding claims, wherein the sample is obtained from a subject suspected having a viral infection.
A kit comprising a primer having at least 90% sequence identity to SEQ ID NO:
- 1, a primer having at least 90% sequence identity to SEQ ID NO:
- 2, a primer having at least 90% sequence identity to SEQ ID NO:
- 4, a primer having at least 90% sequence identity to SEQ ID NO:
- 6, a primer having at least 90% sequence identity to SEQ ID NO:
- 7, and a primer having at least 90% sequence identity to SEQ ID NO:
- 8.
The kit of any one of claims 30-34, further comprising pyrophosphatase.
Dependencies are inferred from the claim text.